I also found it interesting that Fragile X is going to be a pivotal study. AFAIK there hasn't been a P2 Fragile X study, so this one is going straight to pivotal. Same for the unnamed rare disease.
With the Rett pediatric trial that is the three pivotal trials. Nice.
6:10 into the presentation.
As they say...three shots on goal.
Also Missling again pointed out that the PDD data showed positive dose related effects in PDD that is also a primary end point in the AD 450 subject trial. That is a big deal.
Market Data 
Markets 
AI
